JP2009543843A5 - - Google Patents

Download PDF

Info

Publication number
JP2009543843A5
JP2009543843A5 JP2009519955A JP2009519955A JP2009543843A5 JP 2009543843 A5 JP2009543843 A5 JP 2009543843A5 JP 2009519955 A JP2009519955 A JP 2009519955A JP 2009519955 A JP2009519955 A JP 2009519955A JP 2009543843 A5 JP2009543843 A5 JP 2009543843A5
Authority
JP
Japan
Prior art keywords
disease
compound
pharmaceutical composition
group
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009519955A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009543843A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/057256 external-priority patent/WO2008009639A2/en
Publication of JP2009543843A publication Critical patent/JP2009543843A/ja
Publication of JP2009543843A5 publication Critical patent/JP2009543843A5/ja
Pending legal-status Critical Current

Links

JP2009519955A 2006-07-17 2007-07-13 直接トロンビン阻害剤に関する新規適応 Pending JP2009543843A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06117345 2006-07-17
EP07102513 2007-02-15
PCT/EP2007/057256 WO2008009639A2 (en) 2006-07-17 2007-07-13 New indications for direct thrombin inhibitors

Publications (2)

Publication Number Publication Date
JP2009543843A JP2009543843A (ja) 2009-12-10
JP2009543843A5 true JP2009543843A5 (https=) 2010-09-24

Family

ID=38819790

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009519955A Pending JP2009543843A (ja) 2006-07-17 2007-07-13 直接トロンビン阻害剤に関する新規適応

Country Status (7)

Country Link
US (2) US20080200514A1 (https=)
EP (1) EP2043632A2 (https=)
JP (1) JP2009543843A (https=)
AR (1) AR062057A1 (https=)
CA (1) CA2657269A1 (https=)
TW (1) TW200813012A (https=)
WO (1) WO2008009639A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2010143901A (ru) * 2008-03-28 2012-05-10 Бёрингер Ингельхайм Интернациональ Гмбх (De) Способ получения композиций дабигатрана для перорального введения
JP2011515438A (ja) * 2008-03-28 2011-05-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸ペレットの製造方法
BRPI0915942A2 (pt) 2008-07-14 2019-04-09 Boehringer Ingelheim International Gmbh método para produção de compostos medicinais contendo dabigatrana
CA2734809A1 (en) * 2008-08-19 2010-02-25 Boehringer Ingelheim International Gmbh Dabigatran in tumour therapy
JP2013510072A (ja) 2008-11-11 2013-03-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 従来のワルファリン治療に対して安全性プロフィールが改善されたダビガトランエテキシレートまたはその塩を使用して血栓症を治療または予防するための方法
EP2391893B1 (en) * 2009-02-02 2014-09-03 Boehringer Ingelheim International GmbH Lyophilised dabigatran
US20120142703A1 (en) * 2009-05-14 2012-06-07 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases
WO2010130758A1 (en) * 2009-05-14 2010-11-18 Boehringer Ingelheim International Gmbh New combination therapy in treatment of cancer and fibrotic diseases
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
EP2542224B1 (en) * 2010-03-01 2014-08-13 Ratiopharm GmbH Dabigatran etexilate-containing oral pharmaceutical composition
SI2550966T1 (sl) * 2011-07-25 2017-01-31 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg Estri amidoksim karboksilne kisline dabigatrana kot predzdravila in njihova uporaba kot zdravila
US20130345262A1 (en) 2012-06-25 2013-12-26 Boehringer Ingelheim International Gmbh Method for prevention of stroke
CN105440017B (zh) * 2014-08-19 2018-03-02 天津药物研究院 达比加群酯香草酸盐及其制备方法和应用
CN104628733A (zh) * 2015-03-02 2015-05-20 中国药科大学 四氢苯并[4,5]咪唑并[1,2-a]吡嗪类凝血酶抑制剂
WO2025136810A1 (en) * 2023-12-19 2025-06-26 The Research Institute At Nationwide Children's Hospital Anticoagulants for treating nephrotic syndrome

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2258915A1 (en) * 1996-06-25 1997-12-31 Michael Robert Wiley Anticoagulant agents
US5863292A (en) * 1996-09-26 1999-01-26 Tosic; Aleksandar Articulated external orthopedic fixation system and method of use
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
GB0014136D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10235639A1 (de) * 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
AU2003272591A1 (en) * 2002-09-23 2004-04-08 The Regents Of The University Of Michigan Glioma treatments
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
AU2004231306A1 (en) * 2003-04-24 2004-11-04 Boehringer Ingelheim International Gmbh Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors
EP1648232A4 (en) * 2003-07-17 2009-12-30 Smithkline Beecham Corp ARGATROBAN TREATMENT METHOD FOR PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis

Similar Documents

Publication Publication Date Title
JP2009543843A5 (https=)
US9855276B2 (en) Combination therapies for the treatment of Alzheimer's disease and related disorders
JP2020514318A5 (https=)
JP2007533741A5 (ja) Ｂａｃｅ阻害剤として有用なピロリジン誘導体
JP2014518853A5 (https=)
CY1111500T1 (el) Οπιοειδη για τη θεραπεια χρονιας αποφρακτικης πνευμονοπαθειας (copd)
MX356032B (es) Compuestos indola y métodos para tratar el dolor visceral.
CY2017014I2 (el) Φαρμακευτικοι συνδυασμοι που περιεχουν βενζοξαζινες για τη θεραπεια νοσων των αναπνευστικων οδων
KR20110071050A (ko) 알츠하이머 질환 및 관련 장애의 치료를 위한 조니사미드 및 아캄프로세이트의 조합 조성물
JP2021502387A5 (https=)
JP2006517591A5 (https=)
JP2017505293A5 (https=)
JP2009543843A (ja) 直接トロンビン阻害剤に関する新規適応
JP2020512337A5 (https=)
JP2008513498A5 (https=)
JP2013531028A5 (https=)
UA115861C2 (uk) Лікарська форма пірфенідону у вигляді капсул з фармацевтично прийнятними ексципієнтами
TW202317103A (zh) 克立咪唑(clemizole)化合物於預防及治療肝癌之用途
JP2020514316A5 (https=)
FI3856182T3 (fi) Koostumuksia ja menetelmiä muskariinireseptorin aktivaation lievittämien häiriöiden hoitamiseksi
JP2009541443A5 (https=)
RU2006134004A (ru) Производные гетероариламинопиразола, пригодные для лечения диабета
RU2015121043A (ru) Производные фенилэтилпиридина в качестве ингибиторов PDE-4
JP2011500621A5 (https=)
JP2009543844A5 (https=)